Skip to main content
STADA Arzneimittel AG logo

STADA Arzneimittel AG — Investor Relations & Filings

Ticker · SAZ ISIN · DE0007251803 LEI · 529900FMTTLMH0P0DL10 HM Manufacturing
Open in API
Filings indexed 916 across all filing types
Latest filing 2012-01-31 M&A Activity
Country DE Germany
Listing HM SAZ

About STADA Arzneimittel AG

https://www.stada.com/

STADA Arzneimittel AG is a pharmaceutical company that operates on a three-pillar strategy consisting of generics, consumer healthcare products, and specialty pharmaceuticals. The company is a leading manufacturer of affordable generic medicines, which have been a core part of its business since its founding. In the consumer healthcare segment, STADA markets a wide portfolio of over-the-counter (OTC) products and well-known brands. The specialty pharmaceuticals division focuses on developing and marketing value-added medicines, including an expanding portfolio of biosimilars for therapeutic areas such as oncology, immunology, and bone health.

Recent filings

Filing Released Lang Actions
STADA: Purchase of a branded product portfolio for the EU markets in Central Europe successfully concluded
M&A Activity Classification · 99% confidence The document is an 'Ad-hoc' announcement dated January 31, 2012, explicitly mentioning 'Key word(s): Mergers & Acquisitions'. The content details the successful conclusion of the purchase of a branded product portfolio and associated sales structures, referencing prior ad hoc releases regarding contract negotiations, signing, and conclusion of similar deals. This clearly falls under the category of M&A Activity, which corresponds to the TAR filing code.
2012-01-31 English
STADA: Purchase of a generics business in Switzerland successfully concluded
M&A Activity Classification · 99% confidence The document is an 'Ad-hoc' announcement dated January 31, 2012, detailing the successful conclusion of the purchase of a generics business in Switzerland from Spirig Pharma AG. Key phrases include 'Purchase of a generics business,' 'Mergers & Acquisitions,' and specific details about the purchase price and acquired assets. This clearly falls under the category of corporate activity related to mergers or takeovers. Based on the provided definitions, 'M&A Activity (Code: TAR)' is the most appropriate classification.
2012-01-31 English
STADA and Grunenthal agreed on the purchase of a branded product portfolio also for the EU markets in Central Europe at a lower purchase price
M&A Activity Classification · 98% confidence The document is an 'Ad-hoc' announcement dated January 27, 2012, detailing an agreement between STADA Arzneimittel AG and Grünenthal GmbH regarding the purchase of a branded product portfolio. The key phrase is 'Key word(s): Mergers & Acquisitions'. This clearly indicates a significant corporate transaction involving acquisition/merger activity. Based on the provided definitions, the most appropriate classification is 'M&A Activity' (Code: TAR). Although it is disseminated via DGAP (which might suggest RNS), the specific content is about a merger/takeover proposal/agreement, making TAR the precise fit.
2012-01-27 English
STADA: Withdrawal from purchase of the Grunenthal branded product portfolio in Central Europe
M&A Activity Classification · 99% confidence The document is an 'Ad-hoc' announcement dated January 1, 2012, concerning STADA Arzneimittel AG exercising its right to withdraw from the purchase of a branded product portfolio from Grünenthal due to lack of anti-trust approval. This event directly relates to a proposed merger or takeover activity that has now been terminated. Based on the provided definitions, the category 'M&A Activity (Code: TAR)' is the most appropriate fit, as it covers merger proposals or takeover bids, which includes the termination of such agreements.
2012-01-01 English
STADA: Purchase of a branded product portfolio in Eastern Europe as well as in the Middle East successfully concluded - Central Europe still open
Regulatory Filings Classification · 100% confidence The document is an 'Ad-hoc' announcement dated December 30, 2011, explicitly mentioning 'Mergers & Acquisitions' as a keyword. The content details the successful conclusion of the purchase of a branded product portfolio in Eastern Europe and the Middle East, referencing prior ad hoc releases regarding contract negotiations and signing. This clearly indicates an announcement related to a significant corporate transaction involving acquisition/merger activity. Therefore, the appropriate classification is M&A Activity (TAR). The document length is short (3129 chars) and it is an announcement, not the final detailed report, but TAR is a specific event classification, not a report publication announcement (RPA).
2011-12-30 English
STADA subsidiary increases commitment to charity
Environmental & Social Information Classification · 99% confidence The document is a short corporate news release dated December 5, 2011, detailing STADA's increased commitment to charity through donations to the RED NOSE DAY campaign and support for dolphin aid e.V. It is not a formal financial report (like 10-K, IR, ER), nor is it a specific regulatory filing like a Director's Dealing (DIRS) or a Dividend Notice (DIV). It is a general announcement about corporate social responsibility (CSR) activities. Since CSR/ESG information is specifically covered by the 'Environmental & Social Information' category (SR), this is the most appropriate classification, although it is a very light form of SR. Given the options, SR is the best fit for social responsibility news. It is too specific for the general fallback (RNS).
2011-12-05 English

Browse filings by year

28 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.